Показники систем коагуляції та фібринолізу, маркери запалення у хворих на цукровий діабет 2-го типу з ожирінням
DOI:
https://doi.org/10.24026/1818-1384.2(43).2013.77484Ключові слова:
type 2 diabetes mellitus, obesity, coagulation and fibrinolytic system components, markers of inflammationАнотація
The author presents the data on a study of the markers of inflammation levels and state of the coagulation and fibrinolytic system components systems in patients with type 2 diabetes mellitus (DM) and visceral obesity in connection with cardiovascular diseases risk factors. With this purpose, 56 patients have been followed up. The control group included 20 patients corresponding on age and durations of type 2 DM but without abdominal obesity. It has been shown that procoagulant changes are marked at absolute majority of type 2 DM patients with visceral obesity (94.6%), in 64.3% patients these changes were connected with the defeat of a few links of the coagulation blood system. The most frequent changes of hemostasis is an increase of activity of plasminogen activator inhibitor 1 (87.5%), that represents insufficiency of fibrinolysis; increase of activity of coagulation factor VIII (53.6%) and testifies to activating of external cascade of hemopexis, and insufficiency of the anticoagulating system of protein C (23.2%). Chronic subacute system inflammation in type 2 DM patients with visceral obesity shows up the reliable increase of concentration of markers of inflammation – fibrinogen and Ñ-reactive protein, and also by the decline of adiponectin level. Expressed of proinflammatory and procoagulanting changes in patients with type 2 DM and visceral obesity associated with the anthropometric and biochemical markers of obesity.
Посилання
Vazzana N. Diabetes mellitus and thrombosis / N. Vazzana, P. Ranalli, C. Cuccurullo, G. Davi // Thromb. Res. – 2012. – Vol. 129, №3. – P. 371-377. https://doi.org/10.1016/j.thromres.2011.11.052
Alessi M.C. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance / M.C. Alessi, M. Poggi, I. Juhan-Vague // Curr. Opin. Lipidol. – 2007. – Vol. 18, №3. – P. 240-245. https://doi.org/10.1097/mol.0b013e32814e6d29
Братусь В. В. Ожирение, инсулинорезистентность, метаболический синдром: фундаментальные и клинические аспекты / В. В. Братусь, Т. В. Талаева, В. А. Шумаков. - К.: Четверта хвиля, 2009. - 416 с.
Yong W. Remission of insulin resistance in type 2 diabetic patients after gastric bypass surgery or exenatide therapy / W. Yong, W. Shibo, L. Jingang // Obes. Surg. – 2012. – Vol. 22, №7. – P. 1060-1067. https://doi.org/10.1007/s11695-012-0632-1
Undas A. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome / A. Undas, I. Wiek, E. Stepien [et al.] // Diabetes Care. – 2008. – Vol. 31, №8. – P. 1590-1595. https://doi.org/10.2337/dc08-0282
Крамарева В. Н. Уровни маркеров тромбинемии и тромбообразования у больных эссенциальной артериальной гипертензией с кардиоваскулярным риском / В. Н. Крамарева, В. Г. Гриценко, И. Н. Колесникова (и др.) // Науковий вісник Національного медичного університету імені О. О. Богомольця. - 2009. - № 4. - С. 177-180.
Ibrahim M.M. Subcutaneous and visceral adipose tissue: structural and functional differences / M.M. Ibrahim // Obes. Rev. – 2010. – Vol. 11, №1. – P. 8-11. https://doi.org/10.1111/j.1467-789x.2009.00623.x
Берковская М. А. Метаболлический синдром как протромбогенное состояние. / М. А. Берковская, С. А. Бутрова // Ожирение и метаболизм. - 2009. - № 3 (20). - С. 3-9. https://doi.org/10.14341/2071-8713-5239
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Авторське право (c) 2017 Клінічна ендокринологія та ендокринна хірургія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
